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Introduction. There is not much evidence regarding clinical behavior of bladder cancer in younger patients. We evaluated clinical
characteristics, tumor recurrence and progression in patients younger than 40 years old with urothelial bladder carcinoma.
Methods. We retrospectively reviewed the medical records of 31 patients less than 40 years old who were ﬁrstly managed with
bladder urothelial carcinoma in our department. Data were analysed with the Chi-square test. Results. Mean age was 31.7 years.
Mean followup was 38.52 months (11–72 months). Nineteen (61%) patients were diagnosed with GII and 2 (6%) patients with
GIII disease. Five (16%) patients presented with T1 disease. Three (9%) patients with invasive disease underwent cystectomy and
adjuvant chemotherapy and one developed metastatic disease. Ten (32%) patients recurred during followup with a disease free
recurrence rate of 65% the ﬁrst 2 years after surgery. From those, 1 patient progressed to higher stage and three to higher grade
disease. No patient died during followup. Conclusions. Bladder urothelial carcinoma in patients younger than 40 years is usually
low stage and low grade. Management of these patients should be according to clinical characteristics and no diﬀerent from older
patients with the same disease.
1.Introduction
Bladder cancer is a disease that aﬄicts mostly the middle-
agedortheelderlypeople,asthemajorityofanyothercancer
type. The median age of diagnosis of bladder urothelial
carcinoma is 69 years in males and 71 years in females,
but the disease can occur at any age, even in children
[1, 2]. Studies provide evidence that p53 gene product
overexpression is common in bladder cancer in young
patients [3]. There is still conﬂicting evidence regarding
clinical behavior, disease recurrence, and progression in
young patients who have been diagnosed with urothelial
bladder carcinoma. The primary aim of this study is
to evaluate clinical characteristics, disease recurrence, and
progression in patients up to 40 years of age who have been
diagnosed and treated with urothelial bladder cancer in our
department.
2. Patients andMethods
We retrospectively reviewed the medical records of 31
consecutive patients aged 40 years or younger with bladder
urothelial carcinoma, which have been initially diagnosed
andtreatedinourdepartment.Datawererecordedregarding
their presenting symptoms, family history, and any exposure
to occupational risk factors. The time from the onset of
symptoms until the diagnosis was established, and initial
transurethral resection pathology, tumor diameter and loca-
tion, mode of intravesical instillation therapy, number of
recurrences,timetillﬁrstrecurrence,anddiseaseprogression
to diﬀerent stage or grade were also collected and recorded.
Staging and grading of bladder cancer was evaluated accord-
ing to the tumor node metastasis classiﬁcation (TNM) and
the World Health Organization (WHO) [4, 5]. The mean
follow-up period was 38,52 months (11 to 72 months). Data2 Advances in Urology
were analyzed with the Chi-square test. A P Value of less
than 0.05 was considered statistically signiﬁcant. Data were
analyzed using SPSS version 13.
3. Results
Between February, 2003 and January, 2010, thirty-one
patients (19 males and 12 females) with a mean age at
the time of diagnosis of 31.7 years (21–39 years) were
ﬁrstly diagnosed with bladder urothelial carcinoma in our
department. In our series, the male-to-female ratio was
1,6:1. Fourteen patients (45,16%) were under the age of
30, and seventeen (54,83%) patients were between 31 and
40 years old. Macroscopic hematuria was the presenting
symptom in 25 (80.6%) patients. Twenty seven (87%) of
our patients were cigarette smokers, with a mean number of
411 packs per year, which shows a strong relation between
tobacco smoking and bladder cancer. Cigarette smoking is
a known prominent risk factor, which triples the risk of
developing bladder cancer [6–8]. The clinical characteristics
of young patients with bladder cancer are presented in
Table 1. The mean time from the onset of symptoms until
diagnosis was established was 78,64 days (range 9–134
days). Ultrasound of the urinary tract was diagnostic in all
cases. Cystoscopy, also, conﬁrmed the ultrasound ﬁndings
in all cases. Four of them (13%) had a family history
of bladder cancer, and one of them had a family history
of kidney cancer. Regarding exposure to occupational risk
factors, three (9,6%) patients were working as plumber,
motor mechanic, and car body repairer/painters. One female
patient who presented with invasive bladder cancer had
neurogenic lower urinary tract dysfunction managed with
intermittent self-catheterizations and was suﬀering from
recurrent urinary tract infections. All of them underwent
transurethral resection of bladder tumor with additional
biopsies from the tumor base. Final pathology revealed 28
(90%) patients with superﬁcial urothelial bladder cancer and
3 (10%) patients with invasive disease. The overall mean
tumor volume was 4,65cm3 (1,1–16,8cm3), and the mean
tumor diameter was 1.4cm (0.6–5.2cm). Totally, 10 (32,2%)
patients presented with multiple tumors (>2t u m o r s )a t
the time of diagnosis. The majority (58%) of the tumors
were located in bladder trigone. Twelve (42%) patients
with superﬁcial bladder cancer had postoperative intraves-
ical instillation therapy. Seven patients received epirubicin
and 5 patients with high-grade disease received adjuvant
BCG therapy. Overall, ten (32%) patients recurred during
followup with a 65% disease free recurrence rate the ﬁrst 2
years after surgery. Seven (25%) patients had 1 recurrence,
two (7%) patients had 2 recurrences, and one patient had
3 recurrences. In the ﬁrst year, recurrences were four times
more in patients over 30 years old. Three patients progressed
to higher grade (grade II to grade III) and one to higher to
higher stage (Ta to T1). All patients (2 males and 1 female)
with invasive bladder cancer underwent radical cystectomy
(2 received ileal conduit, and 1 had Studer pouch). Two of
them received adjuvant cisplatin-based chemotherapy. The
patient with T3 disease developed metastasis to the lungs.
None of the patients died during followup.
4. Discussion
Urothelial carcinoma of the urinary bladder is rare in young
adults, as less than 1% of such tumors present in the ﬁrst
4 decades of life [9]. Although many reports exist regarding
clinical characteristics and treatment for such tumors, there
is still much debate regarding clinical progression and
prognosis. Indeed, some groups observed similar patterns
of clinical behavior and prognosis for bladder cancer in
young and older patients [10], whereas other investigators
reportedlowerratesofrecurrenceandprogressionandbetter
survival in younger patients [11–13]. Comparative data of
the larger series in the literature of young adults with bladder
cancer, regarding recurrence and progression, are presented
in Table 2. In our study, 50% of patients under 30 years old
presentedwithgradeIIdisease,while70%ofpatientsover30
years old had grade II disease. Furthermore, in the younger
group, four patients (28%) had a recurrence but only one
progressed to higher stage and one to higher grade. In the
older group, six patients (35%) had a recurrence, but only
two of them progressed to higher grade disease. In our study,
none of the patients under 30 years of age presented with
invasive bladder cancer, as opposed to the older age group,
which included 3 patients (9%) with invasive disease.
Ourﬁndingsaddtothegrowingevidenceoftheliterature
that patients under 40 years old usually present with low-
stage and low-grade bladder cancer. Clinical behavior of
high stage and high-grade disease seem to be similar to
older people. Those patients should be managed aggressively
especially when unfavorable prognostic factors coexist such
as multifocality, high grade and stage, and tumors >3cm
[14–16].
An important ﬁnding of our study was the signiﬁcant
delay of approximately 80 days from the onset of symptoms
till diagnosis was established with an ultrasound. This seems
to be common in younger patients due to low incidence
of bladder cancer in this age group and the predominance
of benign causes of hematuria in this age group causing
hesitancy for an aggressive work-up.
In a recent meta-analysis, Paner et al. concluded that
tumor recurrence and progression were infrequent in the
ﬁrst 2 decades and increased gradually in each successive
decade, likely inﬂuenced by the increased proportion of
higher-grade and higher-stage tumors [19]. In the presence
of gross hematuria, a urinary tract ultrasound is the ﬁrst
work-up for establishing the diagnosis of bladder tumor.
Although it cannot replace cystoscopy, it is a reliable
diagnostic tool for the detection of bladder tumor espe-
cially for those young patients who hesitate to undergo a
diagnostic cystoscopy. This observation was conﬁrmed in
our study, since all patients with an ultrasound ﬁnding
of a bladder lesion were found to have bladder tumor in
cystoscopy.
Ofcourse,therearepossiblelimitationsinourstudy.This
is a retrospective audit with small number of patients and
relatively sort followup, although similar to prior reports,
making safe conclusions diﬃcult to extract. Further larger
well-conducted prospective studies with longer followup areAdvances in Urology 3
Table 1: Presentation, clinical characteristics, and treatment modalities of young patients with bladder cancer.
Clinical characteristics of patients <40 years old treated for bladder cancer
Age (yr)
≤30 31–40 Total P∗
Patients, n (%) 14 (45.16) 17 (54,83) 31 (100)
Mean age (range), yr 26,14 (21–30) 37,29 (31–39)
Males/females 9/5 10/7 19/12 P = 0.46
Clinical characteristics at presentation
(i) Macroscopic hematuria 10 15 25
(ii) UTIs 1 1 2
(iii) Microscopic hematuria 3 1 4
Mean followup (range), mo 39,36 37,68 38,52
Multifocality of bladder tumors (>2 lesions) 4 6 10 P = 0.39
Stage at presentation, n
(i) Ta 10 13 23
(ii) T1 4 1 5
(iii) T2 0 2 2
(iv) T3 0 1 1
(v) T4 0 0 0
Grade at presentation, n
(i) Low (GI-II) 14 15 29
(ii) High (GIII) 0 2 2
Recurrence rate (%) 4 (28) 6 (35) 10 (32) P = 0.28
Intravesical therapy of superﬁcial cancer n (%) 7/14 5/14 12/28
Cystectomy, n (%) 0 3 3
Adjuvant chemotherapy for invasive cancer, n
(%) 02 2
















Wen et al. [9] 30 72,8 76,6 23,4 50 8,3
Yossepowitch and
Dalbagni [22] 74 28,1 83,4 16,6 38,7 16
Er˝ ozenci et al. [18] 156 87 89,1 10,9 48,7 22,8
Perez et al. [17] 30 66 67,6 23,3 32 0,1
needed to conﬁrm long-term progression and outcomes
especially in young adults with invasive urothelial bladder
cancer.
In children, adolescents, and young adults less than
20 years old, bladder TCC has a very low recurrence rate
with excellent prognosis [20]. These ﬁndings should not be
extrapolated to describe clinical behaviour of bladder TCC
in patients between 30 to 40 years old who usually present
with higher grade and stage and tend to recur more often
[21, 22].
5. Conclusion
Younger patients with bladder cancer appear to have a
more favorable prognosis, because they usually present with
superﬁcial stage and low-grade tumors. However, the risk
of disease progression is the same, inﬂuenced by grade and
stage at the time of presentation. Patients younger than 40
years old diagnosed with bladder cancer should be oﬀered
the same stage and grade appropriate management as older
ones.4 Advances in Urology
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